Page last updated: 2024-11-04

vorinostat and Reperfusion Injury

vorinostat has been researched along with Reperfusion Injury in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wang, J1
Deng, M1
Wu, H1
Wang, M1
Gong, J1
Bai, H1
Wu, Y1
Pan, J1
Chen, Y1
Li, S1

Other Studies

1 other study available for vorinostat and Reperfusion Injury

ArticleYear
Suberoylanilide hydroxamic acid alleviates orthotopic liver transplantation‑induced hepatic ischemia‑reperfusion injury by regulating the AKT/GSK3β/NF‑κB and AKT/mTOR pathways in rat Kupffer cells.
    International journal of molecular medicine, 2020, Volume: 45, Issue:6

    Topics: Animals; Autophagy; Glycogen Synthase Kinase 3 beta; Kupffer Cells; Liver; Liver Diseases; Liver Tra

2020